抗LGI1、抗NMDAR与抗GABABR脑炎癫痫发作治疗评估
该全国性队列研究纳入153例抗LGI1、抗NMDAR和抗GABABR脑炎患者,其中72%出现癫痫发作,89%达到无发作。至少53%在免疫治疗后不久实现无发作,仅14%单用抗癫痫药物(AEDs)实现无发作(p<0.0001);从开始免疫治疗到无发作的中位时间28天,短于AEDs的59天(p<0.0001)。结论认为免疫治疗是关键,AEDs应作为附加治疗。
要点
- 自身免疫性脑炎相关癫痫发作经免疫治疗无发作率更高、更快。
- 单用AEDs实现无发作比例低,AEDs宜作为附加治疗。
- 抗LGI1脑炎中卡马西平减少发作优于左乙拉西坦。
核心结论
- 在免疫治疗的自身免疫性脑炎队列中,脑炎缓解后发展为癫痫罕见。
- 免疫治疗后无发作实现更快且更频繁,AEDs应作为附加治疗,免疫治疗至关重要。
研究设计与样本
- 全国性队列研究,纳入抗LGI1、抗NMDAR和抗GABABR脑炎伴新发癫痫发作的患者。
- 共153例自身免疫性脑炎患者(53例LGI1、75例NMDAR、25例GABABR),收集病程、AEDs与免疫治疗使用、疗效及副作用信息。
主要发现
- 153例中72%(n=110)有癫痫发作,89%达到无发作。
- 至少53%在免疫治疗后不久实现无发作,14%仅用AEDs实现无发作(p<0.0001)。
- 从开始AEDs到无发作中位时间59天(IQR 27-160),从开始免疫治疗为28天(IQR 9-71,p<0.0001)。
- 抗LGI1脑炎中卡马西平减少发作优于左乙拉西坦(p=0.031)。
- 86例存活患者中仅1例在脑炎缓解后发展为癫痫。
关键数值与推荐
- 无发作定义为使用AEDs或免疫治疗期间无癫痫发作。
- 副作用包括左乙拉西坦引起的精神病行为和自杀念头,卡马西平引起的皮疹。
临床怎么用
- 对自身免疫性脑炎相关癫痫发作,应优先考虑免疫治疗,AEDs作为附加治疗。
- 抗LGI1脑炎患者可考虑卡马西平而非左乙拉西坦减少发作。
- 使用左乙拉西坦需警惕精神病行为和自杀念头,使用卡马西平需警惕皮疹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This nationwide cohort study evaluates seizure responses to immunotherapy and antiepileptic drugs (AEDs) in patients with anti-leucine-rich glioma-inactivated 1 (LGI1), anti-NMDA receptor (NMDAR), and anti-gamma-aminobutyric-acid B receptor (GABABR) encephalitis. METHODS: Anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis patients with new-onset seizures were included. Medical information about disease course, AEDs and immunotherapies used, effects, and side effects were collected. Outcome measures were (1) seizure freedom while using AEDs or immunotherapy, (2) days to seizure freedom from start of AEDs or immunotherapy, and (3) side effects. RESULTS: Of 153 patients with autoimmune encephalitis (AIE) (53 LGI1, 75 NMDAR, 25 GABABR), 72% (n = 110) had epileptic seizures, and 89% reached seizure freedom. At least 53% achieved seizure freedom shortly after immunotherapy, and 14% achieved seizure freedom while using only AEDs (p < 0.0001). This effect was similar in all types (p = 0.0001; p = 0.0005; p = 0.013, respectively). Median time to seizure freedom from AEDs start was 59 days (interquartile range [IQR] 27-160), and 28 days from start of immunotherapy (IQR 9-71, p < 0.0001). Side effects were psychotic behavior and suicidal thoughts by the use of levetiracetam, and rash by the use of carbamazepine. Carbamazepine was more effective than levetiracetam in reducing seizures in anti-LGI1 encephalitis (p = 0.031). Only 1 patient, of 86 surviving patients, developed epilepsy after resolved encephalitis. CONCLUSION: Epilepsy after resolved encephalitis was rare in our cohort of patients with AIE treated with immunotherapy. In addition, seizure freedom is achieved faster and more frequently after immunotherapy. Therefore, AEDs should be considered as add-on treatment, and similar to treatment of other encephalitis symptoms, immunotherapy is crucial.
引用
- de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019. PMID: 30979857. doi:10.1212/WNL.0000000000007475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。